Shares of Nymox Pharmaceutical (NYMX +25.2%) soar today, going out at their highs as the company...

|About: Nymox Pharmaceutical Corpor... (NYMX)|By:, SA News Editor

Shares of Nymox Pharmaceutical (NYMX +25.2%) soar today, going out at their highs as the company says it will present data on NX-1207 at the European Association of Urology's annual meeting held in Milan, Italy. NX-1207 is in late stage Phase 3 development in the U.S. for the treatment of BPH, a common condition of older men associated with growth in prostate size as men age.